Tags

Type your tag names separated by a space and hit enter

Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Expert Opin Pharmacother 2017; 18(11):1115-1125EO

Abstract

INTRODUCTION

Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues. Areas covered: In this article, we describe the role of currently available drug therapies for managing acute gout flares and used in reducing serum urate levels. Further, we explore the role of novel small molecular therapies and biologic agents in the treatment of refractory or severe gout symptoms. A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations Databases (1996-June 2017) was conducted utilizing the key words 'gout', 'interleukin-1 inhibitors', 'acute gout', 'gout treatment', 'urate lowering therapies', 'hyperuricemia', 'colchicine', 'pegloticase', 'lesinurad', 'xanthine oxidase', 'xanthine oxidase inhibitors', 'allopurinol', 'febuxostat', 'uricosurics', 'probenecid', and 'benzbromarone'. All published articles regarding therapeutic management of gout and hyperuricemia were evaluated. References of selected articles, data from poster presentations, and abstract publications were additionally reviewed. Expert opinion: Numerous therapies are currently available to managing acute gout flares and for lowering serum urate levels; advances in the understanding of the pathophysiology of this disorder has led to the emergence of targeted therapies and novel biologic preparations currently in development which may improve the clinical management of severe or refractory cases of disease that fail to respond to traditional therapies.

Authors+Show Affiliations

a Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers , The State University of New Jersey , Piscataway , NJ , USA.b Department of Pharmacy Practice and Administration , Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey , Piscataway , NJ , USA. c Department of Pharmacy , Capital Health Regional Medical Center , Trenton , NJ , USA.b Department of Pharmacy Practice and Administration , Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey , Piscataway , NJ , USA. d Department of Pharmacy , Robert Wood Johnson University Hospital , New Brunswick , NJ , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28658988

Citation

Soskind, Rose, et al. "Updates On the Treatment of Gout, Including a Review of Updated Treatment Guidelines and Use of Small Molecule Therapies for Difficult-to-treat Gout and Gout Flares." Expert Opinion On Pharmacotherapy, vol. 18, no. 11, 2017, pp. 1115-1125.
Soskind R, Abazia DT, Bridgeman MB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother. 2017;18(11):1115-1125.
Soskind, R., Abazia, D. T., & Bridgeman, M. B. (2017). Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opinion On Pharmacotherapy, 18(11), pp. 1115-1125. doi:10.1080/14656566.2017.1349099.
Soskind R, Abazia DT, Bridgeman MB. Updates On the Treatment of Gout, Including a Review of Updated Treatment Guidelines and Use of Small Molecule Therapies for Difficult-to-treat Gout and Gout Flares. Expert Opin Pharmacother. 2017;18(11):1115-1125. PubMed PMID: 28658988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. AU - Soskind,Rose, AU - Abazia,Daniel T, AU - Bridgeman,Mary Barna, Y1 - 2017/07/09/ PY - 2017/7/1/pubmed PY - 2017/11/4/medline PY - 2017/6/30/entrez KW - Gout KW - IL-1 inhibitors KW - hyperuricemia KW - lesinurad KW - pegloticase KW - xanthine oxidase SP - 1115 EP - 1125 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 18 IS - 11 N2 - INTRODUCTION: Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues. Areas covered: In this article, we describe the role of currently available drug therapies for managing acute gout flares and used in reducing serum urate levels. Further, we explore the role of novel small molecular therapies and biologic agents in the treatment of refractory or severe gout symptoms. A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations Databases (1996-June 2017) was conducted utilizing the key words 'gout', 'interleukin-1 inhibitors', 'acute gout', 'gout treatment', 'urate lowering therapies', 'hyperuricemia', 'colchicine', 'pegloticase', 'lesinurad', 'xanthine oxidase', 'xanthine oxidase inhibitors', 'allopurinol', 'febuxostat', 'uricosurics', 'probenecid', and 'benzbromarone'. All published articles regarding therapeutic management of gout and hyperuricemia were evaluated. References of selected articles, data from poster presentations, and abstract publications were additionally reviewed. Expert opinion: Numerous therapies are currently available to managing acute gout flares and for lowering serum urate levels; advances in the understanding of the pathophysiology of this disorder has led to the emergence of targeted therapies and novel biologic preparations currently in development which may improve the clinical management of severe or refractory cases of disease that fail to respond to traditional therapies. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/28658988/Updates_on_the_treatment_of_gout_including_a_review_of_updated_treatment_guidelines_and_use_of_small_molecule_therapies_for_difficult_to_treat_gout_and_gout_flares_ L2 - http://www.tandfonline.com/doi/full/10.1080/14656566.2017.1349099 DB - PRIME DP - Unbound Medicine ER -